AI in drug discovery – what it is, where we stand and the path forward

Here’s the truth about AI in drug discovery: we’ve moved past the demo phase and into the grind. The excitement isn’t about a single miracle molecule—it’s about compressing a cosmos of biological possibility into something a GPU can chew through. This matters because drug discovery is the ultimate high-stakes optimization problem, and the bottleneck has shifted from curiosity to compute and data quality. What does this signal? A collision course between pharma and the datacenter. The path forward isn’t just better neural nets—it’s sovereign data pipelines, validated benchmarks, and enough accelerators to train models that don’t hallucinate chemistry. The winners won’t be those with the cleverest algorithm, but those who own the infrastructure and the trust layer. Let’s be clear: hardware scarcity and noisy biological data will humble more than a few unicorns. But that’s the threshold. AI in drug discovery is no longer a sci-fi pitch; it’s an infrastructural war dressed in lab coats. The next blockbuster drug may not be "discovered" in a petri dish—it’ll be mined in a datacenter, one teraflop at a time. {"key_insight":"Drug discovery's bottleneck is now compute and data infrastructure, not algorithms.","confidence":0}